Brief report: A phase II "window-of-opportunity" frontline study of the mTOR inhibitor, temsirolimus given as a single agent in patients with advanced NSCLC, an NCCTG study

Thanyanan Reungwetwattana, Julian R. Molina, Sumithra J. Mandrekar, Katie Allen-Ziegler, Kendrith M. Rowland, Nicholas F. Reuter, Ronnie F. Luyun, Grace K. Dy, Randolph S. Marks, Steven E. Schild, James R. Jett, Alex A. Adjei

Research output: Contribution to journal › Article › peer-review

34 Scopus citations

Fingerprint

Dive into the research topics of 'Brief report: A phase II "window-of-opportunity" frontline study of the mTOR inhibitor, temsirolimus given as a single agent in patients with advanced NSCLC, an NCCTG study'. Together they form a unique fingerprint.

Medicine & Life Sciences